by mheinl | Nov 29, 2023 | Uncategorized, White Papers
Expediting breakthrough medical device reimbursement has become a recent public policy issue. This paper provides evidence of the value of faster reimbursement of new medical devices using a comprehensive dataset of past approved devices. The estimation considers the...
by mheinl | Oct 27, 2023 | Uncategorized
By Tomas Philipson October 24, 2023 More than one year ago, President Biden signed the Inflation Reduction Act (IRA) into law. “His top legislative achievement has many flaws. But by far its most damaging effects will be increased illness and death stemming from...
by davidsanders | Dec 8, 2021 | Uncategorized
https://ecchc.economics.uchicago.edu/files/2021/12/2021-12-08-Energy-and-Commerce-Committee-Drug-Innovation_RankingMemberComments_Reference1.mp4 ...
by jmanor | Sep 14, 2021 | Uncategorized, White Papers
This issue brief reviews the evidence on the impact of price controls on biopharmaceutical innovation and calibrates what this evidence implies for recent price control proposals in the US. A large academic literature estimates the effect of future drug revenues on...
by Matt Fey | Apr 26, 2021 | Uncategorized, White Papers
The spread of COVID-19 in the United States has prompted extraordinary, although often untested, steps by individuals and institutions to limit infections. Schools, restaurants, entertainment venues, and many other places of business were required to close under the...
by Matt Fey | Apr 26, 2021 | Uncategorized, White Papers
Employer-sponsored health insurance (ESI) is over a trillion-dollar market with about 160 million Americans (a majority) participating as plan members, of which about 80 million are policy holders. The policies are valuable not only to employers and employees, but...